Bausch Health Companies
Company
Bausch Health Companies develops one asset, in phase 2 (tonabersat in dry age-related macular degeneration). Mostly small molecule acting on inflammation and GJA1.
- 1
- Asset
- Furthest stage
- Phase 2
- 4
- Trials
- 0
- Signals
Pipeline
1Inhibits gap junctions and hemichannels (specifically connexin 43) to reduce inflammatory signalling.
Phase 2, Small molecule, Inflammation, GJA1, dry age-related macular degeneration
Full company profiles: pipeline, trials, funding and people.
Subsidiaries
11 asset, 4 trials
In the full profile
- Evidence behind the mechanisms2
- Trials6
- Similar companies6